patiromer sorbitex calcium: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
patiromer sorbitex calcium: clinical details
Prescribing considerations
- Not suitable as replacement therapy for life-threatening hyperkalaemia because of delayed onset.
- Limited evidence exists in dialysis, end-stage renal disease and severe hyperkalaemia.
- Assess benefits and risks in people with current or previous severe gastrointestinal disease, bowel obstruction, major gastrointestinal surgery or swallowing disorders.
- People with hereditary fructose intolerance should not receive the selected product because it contains sorbitol.
- Assess carefully in patients at risk of hypercalcaemia because calcium is partly released and may be absorbed.
- Potassium may rise again after discontinuation, particularly if potassium-raising therapies continue.
Contraindications and cautions
- Hypersensitivity to patiromer or the listed excipient, xanthan gum.
Monitoring
- Monitor serum potassium when clinically indicated, including after relevant medicine changes and after patiromer adjustment or discontinuation.
- Monitor serum magnesium after initiation and subsequently as clinically indicated; consider supplementation if hypomagnesaemia develops.
- Monitor serum calcium after initiation and subsequently as clinically indicated, particularly where hypercalcaemia is a concern.
Clinical pharmacology
A non-absorbed cation-exchange polymer containing a calcium-sorbitol counterion complex. It binds potassium within the gastrointestinal lumen, increases faecal potassium excretion and lowers serum potassium without requiring systemic absorption.
Formulation and product differences
- The selected product is an off-white to light-brown powder for oral suspension supplied in sachets.
- The powder remains suspended rather than dissolving and may settle after mixing.
- Xanthan gum is the listed excipient; sorbitol and calcium form part of the counterion complex.
- The prepared suspension can also be administered through compatible nasogastric or gastrostomy tubes followed by a water flush.
patiromer sorbitex calcium preparations and strengths
Oral suspension
Route: Oral
Strengths: 8.4 g, 16.8 g
patiromer sorbitex calcium interactions
Patiromer can bind medicines in the gut and reduce their absorption. Unless specifically exempted, oral medicines should generally be separated by at least three hours.
Ciprofloxacin
Absorption is reduced when taken together; separating administration by three hours prevented the interaction in studies.
Levothyroxine
Absorption is reduced when taken together; separate administration by at least three hours.
Metformin
Absorption is reduced when taken together; separate administration by at least three hours.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.